Gleizal Arnaud, Meon Arnaud, Asselborn Marc, Chauvel-Picard Julie
Department of Craniomaxillofacial Surgery, Centre Hospitalier Nord, Avenue Albert Raimond, 42000, Saint-Étienne, France; Université Jean Monnet, 6 Rue Basse des Rives, 42100, Saint-Étienne, France; Department of Craniomaxillofacial Surgery, Hôpital Femme Mère Enfant, 69 Boulevard Pinel, 69500, BRON, LYON, France; Department of Craniomaxillofacial Surgery, Hôpital Croix Rousse, 103 Grande Rue de la Croix Rousse, 69004, LYON, France; Université Claude Bernard Lyon 1, 43 Boulevard du 11 Novembre 1918, 69100, Villeurbanne, France.
Department of Craniomaxillofacial Surgery, Centre Hospitalier Nord, Avenue Albert Raimond, 42000, Saint-Étienne, France.
J Craniomaxillofac Surg. 2023 Sep;51(9):521-527. doi: 10.1016/j.jcms.2023.06.002. Epub 2023 Jul 8.
The aim of this case series was to complete the literature with six other cases of orthognathic surgery in patients treated with bisphosphonate (BP). The majority of studies concerning oral and maxillofacial surgery focus on dental extractions and implant placement in patients treated with BP. Only 5 cases of orthognathic surgery in patients treated with BP have been reported: four cases for osteogenesis imperfecta and one case for osteoporosis. Six patients were included in the study from January 2009 to December 2020: 3 treated for fibrous dysplasia and 3 treated for osteoporosis. BP treatment was stopped for 2 cases because it was the scheduled end of their treatment for fibrous dyplasia. The other four cases didn't stop taking BP for surgery. No precautions for the prevention of MRONJ were taken. The operative follow-up was uneventful. Mucosal healing was satisfactory for all patients at D15. No material exposure were observed. Bone consolidation appears complete on X-rays and on CT-scans at D45 with disappearance and bone filling of the fracture line associated with the absence of painful mobility of the maxilla and mandible on clinical examination. Until now, all the patients have a stable class I occlusion, no signs of osteonecrosis on X-rays (no signs of bone demineralization, no hypermineralized bone sequestration, no signs of osteolysis) or periodontal disease and healed osteotomies of the jaw without radiological features. No relapse were observed. The management of patients treated with bisphosphonate should be done carefully but orthognathic surgery is no longer a contraindication.
本病例系列的目的是补充另外6例接受双膦酸盐(BP)治疗患者的正颌外科手术文献。大多数关于口腔颌面外科的研究集中在接受BP治疗患者的拔牙和种植体植入。仅报道了5例接受BP治疗患者的正颌外科手术病例:4例为成骨不全,1例为骨质疏松症。2009年1月至2020年12月期间,6例患者纳入本研究:3例因纤维性发育异常接受治疗,3例因骨质疏松症接受治疗。2例患者因纤维性发育异常治疗计划结束而停止BP治疗。其他4例患者手术时未停止服用BP。未采取预防药物性颌骨坏死(MRONJ)的措施。手术随访过程顺利。所有患者术后15天黏膜愈合情况良好。未观察到材料暴露。术后45天X线和CT扫描显示骨愈合完全,骨折线消失且有骨填充,临床检查上颌骨和下颌骨无疼痛性活动。截至目前,所有患者咬合关系稳定为Ⅰ类,X线片无骨坏死迹象(无骨质脱矿迹象、无矿化过度的骨块、无骨溶解迹象)或牙周疾病,颌骨截骨处愈合良好且无放射学异常。未观察到复发情况。对接受双膦酸盐治疗患者的管理应谨慎,但正颌外科手术不再是禁忌证。